Óskare Capital Overview
Óskare Capital is a venture capital firm headquartered in Paris and London, focusing on venture-stage investments in the Deeptech and Life Sciences sectors. The firm targets innovative companies developing novel therapeutics, particularly those interacting with the Endocannabinoid System (ECS), and related industry infrastructure. Their investment portfolio includes companies like Octarine Bio, Herbolea, Leva, Prohibition Partners, and Aelis Farma.
Is Óskare Capital the right investor for your startup? Browse their investment focus, stage preferences, and geographic scope to see how well they align with your fundraising goals. Your full match score with Óskare Capital, along with a list of other relevant VCs, is available on Hopohopo.io.
Óskare Capital
Investment focus
Invest in
- Baltics
- Nordics
- Western Europe
- Southern Europe
- Central Eastern Europe
Product type
- Software-enabled hardware
- Services
- Materials
- Drugs / Pharma
Industries / verticals
- BioTech & Life Sciences
- PharmaTech
Stages
Pre-seed, Seed, Series A
First ticket size
€5,000 - €1,000,000
How to approach funds like Óskare Capital
When approaching Óskare Capital, founders should highlight breakthrough science or technology with clear clinical or commercial potential, especially if their work leverages novel mechanisms or platforms relevant to the Endocannabinoid System. Demonstrate a strong understanding of regulatory pathways and the unique challenges in scaling deeptech or life sciences ventures. Articulate how your team’s expertise and IP position can drive defensible value in a rapidly evolving sector, and be prepared to discuss both scientific rigor and go-to-market strategy.
Find the best-fitting investors for your startup
Stop wasting weeks searching for the right investors. Upload your deck and get matched with investors who actually fit your startup — so you can focus on building, not chasing.
